Increased Protein Synthesis [PE] - N0000009533
Pharmacologic Class Information
Pharmacologic Code | N0000009533 |
Pharmacologic Name | Increased Protein Synthesis |
Pharmacologic Uses |
|
Pharmacologic Concept | Physiologic Effects - [PE] |
Pharmacologic Concept Description | This concept refers to the tissue, organ, or organ system effects of drug generic ingredients, organized into an organ system classification hierarchy, beneath the "Physiological Effects [PE]" concept. |
NDC Products with Increased Protein Synthesis
The table contains 3 products whose active ingredient are classified under the same pharmacologic class Increased Protein Synthesis [PE].
NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
---|---|---|---|---|---|---|---|
50242-175 | Evrysdi | Non-Proprietary Name: Risdiplam | Powder, For Solution | Oral | Genentech Inc. | ACTIVE | |
60923-227 | Amondys 45 | Non-Proprietary Name: Casimersen | Injection | Intravenous | Sarepta Therapeutics, Inc. | ACTIVE | |
64406-058 | Spinraza | Non-Proprietary Name: Nusinersen | Injection, Solution | Intrathecal | Biogen | ACTIVE |